.jpg)
.png)
Last Updated: Thursday, 11-Feb-2021 20:45:00 EST
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved EvkeezaTM (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat adult and pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first FDA-approved treatment that binds to and blocks the function of angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism.
Last Updated: Friday, 15-Jan-2021 13:30:00 EST
The window for nominations to NLA and Chapter leadership positions is now open through February 28, 2021. Open positions include:
National Lipid Association positions include:
- At-Large Board Member (up to 7)
Chapter positions include:
- President-Elect
- Treasurer
- Secretary
- At-Large Board Member (up to 5)
For more information and to nominate your colleagues, visit www.lipid.org/nominate.
Despite the challenges of the ongoing pandemic, SELA continues to stay active by supporting various initiatives that will provide useful resources to our members. SELA is supporting the Foundation of the NLA by providing funds to translate numerous patient handouts on various topics, including triglycerides and hearthealthy grocery shopping.
Article By:
DAVE L. DIXON, PharmD, BCPS, CDE, AACC, FNLA
President, Southeast Lipid Association
Assistant Professor
Vice-Chair of Clinical Services
Director, Center for Pharmacy Practice Innovation
VCU School of Pharmacy
Richmond, VA
The 2020-21 NELA Chapter was happy to co-sponsor this edition of the LipidSpin on Telehealth, and the NELA Chapter board would like to personally thank all NELA/ SELA contributors to this issue.
Article By:
KAREN ASPRY, MD, MS, FACC, FAHA, FNLA
President, Northeast Lipid Association
Director, Lipid and Prevention Program
Lifespan Cardiovascular Institute
Associate Professor of Medicine
Brown University Alpert Medical School
Providence, RI
Diplomate, American Board of Clinical Lipidology
Throughout history, the field of medicine has been innovative in the evaluation, management, and treatment of healthrelated problems, as well as in embracing transformational technologies. One realm of medical innovation that has been brought to the forefront recently is telehealth. The Coronavirus Disease-2019 (COVID-19) pandemic has impacted the economic landscape, altered the way we carry out daily activities, and put an immensurate strain on our healthcare system.
Article By:
ANIL VARUGHESE, MD
Emory Clinical Cardiovascular Research Institute
Division of Cardiology
Emory University School of Medicine
Atlanta, GA
PARTH PATEL, MD
Department of Internal Medicine
Emory University School of Medicine
Atlanta, GA
DEVINDER DHINDSA, MD
Emory Clinical Cardiovascular Research Institute
Division of Cardiology
Emory University School of Medicine
Atlanta, GA
DANNY J. EAPEN, MD
Department of Medicine
Division of Cardiology
Emory University School of Medicine
Atlanta, GA
LAURENCE S. SPERLING, MD, FACC, FACP, FAHA, FASPC
Katz Professor in Preventive Cardiology
Emory University School of Medicine
Professor of Global Health
Hubert Department of Global Health
Rollins School of Public Health at Emory University
Atlanta, GA
Electronic capture and storage of health information is a potentially powerful tool. When electronic information is captured in a way that is translatable across multiple platforms and stored in an easily accessible platform, it provides longitudinal information regarding patients and their health histories that can be used for clinical medicine as well as for quality improvement and research.
Article By:
LANEY K. JONES, PharmD, MPH
Assistant Professor, Genomic Medicine Institute
Geisinger
Danville, PA
DAVID KANN, MD, MPH, FNLA
Director of the Lipid Clinic, Heart Institute
Geisinger
Danville, PA
Diplomate, American Board of Clinical Lipidology
Introduction
Article By:
DEBORAH CROY, DNP, ANP-BC, AGPCNP-BC, CLS, AACC, FNLA
Bland County Medical Clinic
Bastian, VA
MELISSA COLEMAN, RN, BSN, SFNP
Bland County Medical Clinic
Bastian, VA
We can all agree that life has now been forever divided into eras of ‘before and after the coronavirus of 2019 (COVID19)’ with a tidal shift impacting our personal lives and every aspect of medical care, including the traditional healthcare appointment. COVID-19 has highlighted the suboptimal risk factor control of our patients that predisposes them to worse outcomes, disparities in access to clinical care, and the multiple inefficiencies of our current healthcare system.
Article By:
EUGENIA GIANOS, MD, FACC, FASE, FNLA
System Director, Cardiovascular Prevention
Northwell Health
Director, Women’s Heart Health
Lenox Hill Hospital
New York, NY
Diplomate, American Board of Clinical Lipidology
RACHEL NAHRWOLD, AGNP-BC
Nurse Practitioner, Cardiovascular Prevention
Northwell Health
Women’s Heart Health
Lenox Hill Hospital
New York, NY
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)has changed many aspects of our day-to-day life, including healthcare and how it is delivered.(1) This public health emergency has necessitated a shift in the methods utilized to provide patient care.
Article By:
CASEY ELKINS, DNP, MEd, NP-C, CLS, FNLA
Director, DNP Program
Associate Professor Coordinator – Clinical Lipidology
University of South Alabama
College of Nursing
Mobile, AL
ERICA KINDIG, MSN, MS, FNP-C
DNP Student
University of South Alabama
Mobile, AL
Historically, familial hypercholesterolemia (FH), remains an underdiagnosed and undertreated disease. It is estimated that 90% of individuals with FH remain undiagnosed in the United States.(1) FH patients have ten to twenty-fold higher risk of cardiovascular disease. However, cardiovascular risk in this subgroup of patients does not differ significantly from the general population with appropriate early diagnosis and initiation of treatment.
Article By:
CAROLINE deRICHEMOND, CRNP, CLS, FNLA
Advanced Practitioner Cardiology
Geisinger Heart and Vascular Center
Geisinger Wyoming Valley Medical Center
Wilkes Barre, PA
Diplomate, Accreditation Council for Clinical Lipidology
YASSER KHALIL, MD
Associate Cardiology
Geisinger Heart and Vascular Center
Geisinger Wyoming Valley Medical Center
Wilkes Barre, PA
Diplomate, American Board of Clinical Lipidology